BioNTech, Fosun start Phase II trial of COVID-19 vaccine in China

By: |
November 25, 2020 2:44 PM

BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.

Coronavirus, Coronavirus news, Coronavirus updates, Coronavirus vaccine, India corona vaccine, covid updates, corona vaccine news, corona latestThe vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity. (Representational image: Reuters)

BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase II clinical trial of BioNTech’s experimental COVID-19 vaccine in China.

The vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Center for Disease Control and Prevention to assess safety and immunogenicity, eyeing future approval in China, the two companies said in a statement.

BioNTech is also working with U.S. pharma giant Pfizer on the vaccine and the partners said last week they were hoping to win approval in the United States and Europe this year after trial results showed the compound had a 95% efficacy rate and caused no serious side effects.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19: Ahmedabad Corporation makes vaccine mandatory for city buses, tourist places, libraries, check details
2Dr Gagandeep Kang on the road ahead with COVID-19, booster shots & on inoculating approach for children
3Covid vaccines donated by India earlier this year for UN peacekeepers exhausted: UN spokesperson